Accelr8 Begins Disclosure of BACcelr8r(TM) Rapid Pathogen Analysis Operating Principles to the Scientific Community

    DENVER, Feb. 22 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation
 (Amex:   AXK) announced today that the editorial reviewers for two annual
 scientific meetings have accepted Accelr8 scientists' submissions for
 technical poster presentations.  These events represent the company's first
 disclosures to the scientific community of the technical principles used in
 its BACcelr8r(TM) rapid pathogen diagnostic development program.  The posters
 will present data on fundamental scientific elements of the company's methods
 for bacterial analysis (identification, counting, growth measurement, and
 antibiotic resistance testing).
     According to David Howson, Accelr8's president, "these presentations will
 mark Accelr8's first exposure to the scientific community of our unique
 Quantum Microbiology(TM) methods for rapid pathogen analysis.  They reflect
 our progress in eliminating bacterial cultures along our path toward rapid,
 improved measurement of antibiotic resistance in life-threatening hospital
 acquired infections."
     The 38th annual Oak Ridge Conference, entitled "Pushing the Technology
 Envelope III: The Next Generations of Diagnostic Testing" will be held on
 April 20-21 in San Jose, Calif.  It is sponsored by the American Association
 for Clinical Chemistry (AACC, www.aacc.org).  The AACC is a large, US-based
 international scientific/medical society of clinical laboratory professionals,
 physicians, research scientists and other individuals engaged in
 science-related clinical laboratory disciplines.  The Oak Ridge Conference is
 the AACC venue for new science and technology in emerging diagnostics.
     At this conference, Accelr8 scientists will present two technical posters.
 The first will present data derived from novel methods for rapid bacterial
 concentration and rapid species identification in a fluidic device.  The
 second will report growth rate measurements of individual bacteria and their
 descendant clones in the same type of fluidic device.
     The second meeting will be the 106th General Meeting of the American
 Society for Microbiology (ASM, www.asm.org), being held May 21-25 in Orlando,
 Fla.  The ASM is the leading American professional society for
 microbiologists.  At this annual meeting, Accelr8 scientists will present data
 derived from a rapid, clinically-relevant test for an important type of
 antibiotic resistance that has proven difficult to accurately test with
 automated commercial instruments.
     "We look forward to engaging the microbiology community in applying our
 technology for rapid bacterial analysis without culturing," said Howson.
 "These presentations are the first in what we plan to become a growing
 pipeline of peer-reviewed publications that are subjected to independent
 scientific scrutiny. In this early phase we will report the results of basic
 studies using our innovative scientific principles.  We then intend to
 progress to demonstrations of increasingly practical clinical application.  We
 intend ultimately to validate the BACcelr8r as an important new diagnostic
 advance in managing critically ill patients who contract a drug-resistant
 hospital acquired infection (HAI)."
 
     ABOUT ACCELR8
     Accelr8 Technology Corporation (www.accelr8.com) is a developer of
 innovative materials and instrumentation for advanced applications in medical
 diagnostics, basic research, drug discovery, and bio-detection.  Accelr8 is
 developing a new diagnostic platform, the BACcelr8r(TM), based on its
 proprietary surface coatings, assay processing, and detection technologies.
 The company intends the BACcelr8r(TM) to become the world's first diagnostic
 system to provide bacterial identification and quantitation in 2 hours or
 less, and complete antibiotic resistance strain identification in 8 hours or
 less.  Standard culturing typically delays lab results from one to three days,
 which is far beyond the short time window that physicians have available to
 assure adequate initial therapy for a life-threatening hospital acquired
 infection (HAI).
 
     Safe Harbor for Forward-Looking Statements
     Certain statements in this news release may be "forward-looking
 statements" within the meaning of Section 27A of the Securities Act of 1933,
 as amended, and Section 21E of the Securities Exchange Act of 1934, as
 amended.  Statements regarding future prospects and developments are based
 upon current expectations and involve certain risks and uncertainties that
 could cause actual results and developments to differ materially from the
 forward-looking statement, including those detailed in the company's filings
 with the Securities and Exchange Commission.  Accelr8 does not undertake an
 obligation to publicly update or revise any forward-looking statements,
 whether as a result of new information or future events.
 
 

SOURCE  Accelr8 Technology Corporation